Gismo Therapeutics was founded on breakthrough science in the field of Glycosaminoglycan (GAG)-Interacting Small Molecules (GISMO), invented by its founder Dr. Paul Gregor. The program provides a new hypothesis for the cause of Alzheimer’s and Parkinson’s Disease, and is aimed to develop innovative oral therapeutics with a novel mechanism of action and a hitherto unexplored therapeutic principle.


The mechanism of action of GISMO compounds is new and proprietary. Patents to cover GISMO technology are pending. The attached video is for illustration purposes only. All rights are reserved.


GTC-3000 – Alzheimer’s Disease: This project aims to develop a novel disease modifying therapeutic, a GISMO compound targeting pathological consequences of glycosaminoglycan, beta-amyloid and Tau biology and their association. This project has been awarded a SBIR grant from NIA/NIH. Lead compounds have been identified and patent applications are being filed.

GTC-5000 – Parkinson’s Disease: This project, based on advances in alpha-synuclein and GAG biology, aims to develop a novel disease-modifying drug for Parkinson’s Disease and other synucleinopathies. This project has been awarded a Michael J. Fox Foundation for Parkinson’s Disease grant.

GTC-6000 – Alzheimer’s Disease: This project is based on advances in Tau and GAG biology, and aims to provide a new medicine for Alzheimer’s Disease, Frontotemporal Dementia and other tauopathies.

ALZHEIMER’S DISEASE is the sixth leading cause of death in the US, affecting over 5 million Americans every year. Alzheimer’s Disease is an age related disease characterized by progressive dementia, for which there is currently no cure. Memory loss, confusion and inability to take care of basic day to day needs greatly impacts patients and families, often years before the disease reaches the critical stage. For each Alzheimer’s patient, extended family members and care givers are affected, straining emotional and financial resources. With increasing life span due to healthier living and advances in medical care, Alzheimer’s Disease will continue to devastate individuals and families until causes are identified, and a cure for the disease is found.

PARKINSON’S DISEASE is a slowly progressing neurodegenerative disease that destroys cells in the brain region controlling movement, the substantia nigra. Over one million people are diagnosed with Parkinson’s Disease in the US, and an estimated five million people are affected worldwide. The current treatment for Parkinson’s Disease is replacement of the neurotransmitter dopamine, which is lost when dopamine producing cells in the substantia nigra are destroyed by disease. This provides temporary relief for many patients, but there are currently no drugs available that prevent the destruction of neurons in Parkinson’s Disease. New drugs that protect neurons and prevent the spread of disease are essential in order to treat the cause of disease and halt disease progression.